Chemical Property of N-arachidonoylglycine
Chemical Property:
- Boiling Point:560.9 °C at 760 mmHg
- PKA:3.58±0.10(Predicted)
- Flash Point:293 °C
- PSA：66.40000
- Density:0.985 g/cm3
- LogP:5.72380
- Storage Temp.:−20°C
- Sensitive.:Air Sensitive
- Solubility.:DMSO: >5 mg/mL, soluble
- XLogP3:5.6
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:16
- Exact Mass:361.26169398
- Heavy Atom Count:26
- Complexity:476
- Purity/Quality:
-
98%Min *data from raw suppliers
N-Arachidonylglycine ≥98%(HPLC) *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- Safety Statements:
22-24/25
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCC(=O)O
- Isomeric SMILES:CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCC(=O)O
-
Description
Arachidonoyl glycine (N-arachidonyl glycine; NAGly) has been isolated from cell cultures treated with arachidonoyl ethanolamide (AEA; anandamide), from extracts of mammalian brain, and has also been synthesized as an analog of AEA for structure/activity testing. NAGly may be produced endogenously via oxidation of AEA, or by transacylation of arachidonoyl CoA. NAGly is reported to have analgesic activities in whole animal experiments. Since it seems to be a very poor ligand for the CB1 receptor, these effects are probably mediated via other signaling pathways.
-
Uses
Arachidonoyl glycine (N-arachidonyl glycine; NAGly) has been isolated from cell cultures treated with arachidonoyl ethanolamide (AEA; anandamide), from extracts of mammalian brain, and has also been synthesized as an analog of AEA for structure/activity testing. NAGly may be produced endogenously via oxidation of AEA, or by transacylation of arachidonoyl CoA. NAGly is reported to have analgesic activities in whole animal experiments. Since it seems to be a very poor ligand for the CB1 receptor, these effects are probably mediated via other signaling pathways.[Cayman Chemical] An endogenous anandamide-like compound; also acts as a T-type Ca2+ channel blocker and an endogenous GLYT2 inhibitor.
